LAVA exceeds tender offer minimum, plans Nasdaq delisting Nov 13, 2025 07:30AM
XOMA and LAVA amend purchase agreement with lower cash offer Oct 17, 2025 11:47AM
LAVA Therapeutics N.V. (LVTX) Misses Q2 EPS by 2c Aug 13, 2025 05:47PM
Jefferies Downgrades Lava Therapeutics NV (LVTX) to Hold Aug 5, 2025 02:45AM
LAVA Therapeutics N.V. (LVTX) Tops Q1 EPS by 19c May 14, 2025 07:30AM


Mar 31, 2025 06:31AM Lava Therapeutics NV (LVTX) PT Lowered to $1 at Leerink Partners, 'We remain cautious'
Mar 31, 2025 06:06AM Citizens JMP Reiterates Market Perform Rating on Lava Therapeutics NV (LVTX)
Feb 25, 2025 07:02AM LAVA Therapeutics (LVTX) Announces Evaluation of Strategic Options
Jan 10, 2025 08:25AM LAVA Therapeutics (LVTX) Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
Dec 20, 2024 06:44AM Lava Therapeutics NV (LVTX) PT Lowered to $2 at H.C. Wainwright
Dec 12, 2024 06:19AM Leerink Partners Downgrades Lava Therapeutics NV (LVTX) to Market Perform
Dec 11, 2024 02:40AM JMP Securities Downgrades Lava Therapeutics NV (LVTX) to Market Perform
Dec 10, 2024 07:50AM LAVA Therapeutics N.V. (LVTX) Misses Q3 EPS by 13c
Aug 20, 2024 07:37AM LAVA Therapeutics N.V. (LVTX) Tops Q2 EPS by 2c
Jun 28, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Lava Therapeutics NV (LVTX)